Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Regeneron Pharmaceuticals Inc. announced a deal with Melbourne-based Telix Pharmaceuticals Ltd. to co-develop and co-commercialize four programs, with options…
The Regeneron-Telix alliance follows a wave of radiopharma M&A that included Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio (2023), AstraZeneca's…
Regeneron Pharmaceuticals will co-develop 'next generation' radiopharmaceuticals with Australian biotechnology firm Telix. Through a deal announced Monday,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Regeneron and Telix announced a 50/50 cost-and-profit-share collaboration to co-develop next-generation radiopharmaceutical therapies across four initial solid-tumor programs. Telix receives $40M upfront with per-program optionality to co-fund commercialization/profit-share or alternatively earn up to $2.1B in milestones plus low double-digit royalties. Also plans co-developed companion radio-diagnostics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited (this deal) | 2026 | $2.1B | — |
| Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. | 2019 | $1.0B | 77 |
| Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. | 2026 | $4.0B | 62 |
| Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) | 2022 | $1.1B | — |
| Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. | 2025 | $256M | — |
| Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. | 2026 | $2.3B | — |
| Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. | 2025 | $275M | — |
← Browse all deals · How we score deals
More: 2026 deals · Regeneron Pharmaceuticals, Inc. deals · Oncology deals